Johnson & Johnson’s designation as a Dividend King underscores more than six decades of consecutive annual increases, and its current 2.2% yield highlights the company’s defensive income appeal. Revenue diversification across pharmaceuticals, medical devices and consumer health products delivers predictable cash flows that support ongoing dividend commitments even during economic slowdowns.